Loading…
DexCom, Inc. is projected to rise to $80.97 by 2027, a +15% move from its current price of $70.26. DXCM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $68.55 | $70.27 | $72.02 | +0.01% |
| May 30 | $67.86 | $70.27 | $72.77 | +0.02% |
| May 31 | $67.33 | $70.28 | $73.35 | +0.02% |
| Jun 1 | $66.90 | $70.28 | $73.84 | +0.03% |
| Jun 2 | $66.51 | $70.29 | $74.28 | +0.04% |
| Jun 3 | $66.17 | $70.29 | $74.68 | +0.05% |
| Jun 4 | $65.85 | $70.30 | $75.05 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $65.85 | $70.30 | $75.05 | +0.06% |
| Week 2 | $64.13 | $70.34 | $77.15 | +0.12% |
| Week 3 | $62.85 | $70.38 | $78.82 | +0.17% |
| Week 4 | $61.79 | $70.42 | $80.26 | +0.23% |
| Week 5 | $60.88 | $70.46 | $81.55 | +0.29% |
| Week 6 | $60.07 | $70.50 | $82.74 | +0.35% |
| Week 7 | $59.34 | $70.54 | $83.86 | +0.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
DexCom, Inc. is a medical device company that focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. Its portfolio includes Dexcom G7 and G7 15 Day, Dexcom G6, Dexcom ONE+ to replace fingerstick testing for treatment decisions, and Stelo, a biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin.
The company also offers Dexcom Share for remote monitoring and the Dexcom Follow application, and it markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom was incorporated in 1999 and is headquartered in San Diego, California.
DexCom operates within the Healthcare sector, developing and selling medical devices that support diabetes management through CGM technology. The description highlights a broad product lineup and a focus on professional adoption and patient monitoring, painting a picture of a company centered on sensor-based health solutions.
With its long-standing presence and headquarters in San Diego, DexCom positions itself as a leading player in CGM systems, serving markets both in the United States and internationally.
DexCom, Inc. (DXCM) is currently priced at $72.10 per share with a market capitalization of $27.82B, and it sits at rank 474. These figures place the stock among mid-cap healthcare equities with a substantial CGM footprint in its segment.
The forecasted price trajectory shows a rising path, with 2027 and beyond moving into higher-average levels. The expected average price rises to $116.07 by 2030 and to $502.36 by 2050, indicating a long-run upward outlook according to the provided projections.
Near-term and multi-year forecasts are presented as estimates, with 2026 averaging $72.10 and a 30-day window suggesting potential upside within a broader bullish to neutral trend over time. These numbers are not guarantees but provide a framework for possible price development across the coming years.
A major floor 25.8% below — a decisive break under it would weaken the trend.
The nearest floor, 18.1% below — buyers have tended to step in here.
Price is pressing into resistance (2.6% away) — a breakout level to watch.
A major ceiling 15.5% above — clearing it would confirm fresh momentum.
Key DXCM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DXCM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.54 | Sell | $70.26 | Sell |
| MA 10 | $66.78 | Buy | $68.00 | Buy |
| MA 20 | $63.41 | Buy | $65.57 | Buy |
| MA 50 | $63.69 | Buy | $64.79 | Buy |
| MA 100 | $67.11 | Buy | $65.95 | Buy |
| MA 200 | $67.89 | Buy | $68.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.82 | Neutral |
| Stoch RSI (14) | 80.21 | Sell |
| CCI (20) | 99.53 | Neutral |
| Williams %R (14) | -12.89 | Info |
| MACD (12,26,9) | 1.36 | Buy |
| ROC (12) | 15.92 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 87.11 | Sell |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 8.42 | Buy |
| Ultimate (7,14,28) | 77.62 | Sell |
| Momentum (10) | 9.12 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 73.79 | Sell |
| ADX (14) | 23.06 | Buy |
| ATR (14) | 1.48 | Info |
The near-term technical picture is neutral. RSI(14) is 70, and the stock sits between a 50-day simple moving average of $63.46 and a 200-day simple moving average of $67.95.
In terms of support and resistance, the key levels are $57.56 and $72.10, respectively. The 30-day range spans from a low of $60.86 to a high of $85.42, illustrating a broad, exploratory trading band as momentum shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $57.56 | $70.26 | $93.24 | 0% | Neutral | |
| $64.81 | $80.97 | $106.81 | +15% | Neutral | |
| $67.08 | $85.87 | $117.03 | +22% | Bullish | |
| $70.27 | $91.79 | $128.39 | +31% | Bullish | |
| $83.72 | $111.35 | $159.21 | +58% | Bullish | |
| $92.49 | $125.03 | $182.27 | +78% | Bullish | |
| $100.27 | $137.64 | $204.17 | +96% | Bullish | |
| $111.31 | $154.99 | $233.57 | +121% | Bullish | |
| $106.89 | $150.87 | $230.70 | +115% | Bullish | |
| $110.30 | $157.71 | $244.45 | +124% | Bullish | |
| $158.97 | $241.02 | $395.52 | +243% | Bullish | |
| $279.24 | $467.86 | $834.84 | +566% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $57.56 | $70.26 | $82.63 | +0.00% |
| June 2026 | $61.11 | $71.62 | $85.82 | +1.94% |
| July 2026 | $59.95 | $70.79 | $85.87 | -1.16% |
| August 2026 | $59.79 | $71.02 | $86.97 | +0.33% |
| September 2026 | $61.56 | $73.48 | $90.67 | +3.46% |
| October 2026 | $61.98 | $74.33 | $92.35 | +1.14% |
| November 2026 | $60.86 | $73.27 | $91.59 | -1.42% |
| December 2026 | $61.37 | $74.17 | $93.24 | +1.22% |
Click any year to see its month-by-month DXCM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DXCM to range from $57.56 to $93.24 through 2026. The $70.26 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DXCM price prediction for 2027 points to an average of $80.97 (low $64.81, high $106.81) — a potential gain of +15% on today's $70.26. Price action looks broadly range-bound.
In 2028, DXCM is projected to trade between $67.08 and $117.03, averaging $85.87 — a potential gain of +22% from today's $70.26. That is up +6% on the projected 2027 average. Buyers look set to stay in control over this stretch.
DexCom, Inc.'s 2029 outlook centres on $91.79, within a $70.27 to $128.39 range. That is up +7% on the projected 2028 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2030, DXCM could reach as high as $159.21, with a base case around $111.35 and support toward $83.72 — roughly +58% from $70.26. Buyers look set to stay in control over this stretch.
Expect DXCM to range from $92.49 to $182.27 through 2031. The $125.03 average target implies a +78% move from current prices. That is up +12% on the projected 2030 average. Momentum favours further upside here.
The DXCM price prediction for 2032 points to an average of $137.64 (low $100.27, high $204.17) — a potential gain of +96% on today's $70.26. Buyers look set to stay in control over this stretch.
In 2033, DXCM is projected to trade between $111.31 and $233.57, averaging $154.99 — a potential gain of +121% from today's $70.26. That is up +13% on the projected 2032 average. Momentum favours further upside here.
DexCom, Inc.'s 2034 outlook centres on $150.87, within a $106.89 to $230.70 range. That is -3% versus the projected 2033 average. That marks a +115% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DXCM could reach as high as $244.45, with a base case around $157.71 and support toward $110.30 — roughly +124% from $70.26. Momentum favours further upside here.
Expect DXCM to range from $158.97 to $395.52 through 2040. The $241.02 average target implies a +243% move from current prices. That is up +53% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DXCM price prediction for 2050 points to an average of $467.86 (low $279.24, high $834.84) — a potential gain of +566% on today's $70.26. Momentum favours further upside here.
Investing $1,000 in DXCM today (≈ 14.232849 DXCM) could be worth
$6,658.98
+$5,658.98 (+566%) by 2050 · US Dollar
Based on the average projected DXCM price of $467.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DXCMwould be worth at today's price.
$1,000 invested in DXCM on May 27, 2025 (≈ 11.719208 DXCM) would be worth
$823.39
-$176.61 (-17.7%) today · 0.82× · US Dollar
Based on a DXCM entry price of $85.33 vs. today's $70.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.44 | $983.48 | -1.7% |
| 1 month ago | $61.41 | $1,144.11 | +14.4% |
| 3 months ago | $74.38 | $944.61 | -5.5% |
| 6 months ago | $63.47 | $1,106.98 | +10.7% |
| 1 year ago | $85.33 | $823.39 | -17.7% |
| All time (5.0y) ago | $91.42 | $768.56 | -23.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DXCM forecast.
Our base-case forecast reaches $140.00 around 2033.
Implied market cap at $140.00: $54.02B
The multi-year forecast shows a strong bullish tilt from 2028 onward, with 2028 averaging $88.68 and 2029 averaging $95.69, and a notable rise by 2030 to an average of $116.07 with an expected ROI of 61%. The trajectory continues to 2040, where the average is projected at $254.48 and the ROI climbs to 253%. By 2050, the average forecast reaches $502.36 with an ROI of 596.8%.
Forecast sentiment shifts from Neutral in 2026 and 2027 to Bullish from 2028 through 2050, reflecting an increasingly favorable outlook in the model’s view. The implied path suggests substantial upside potential over the longer term, balanced by the inherent uncertainty of investment forecasts.
These are estimates, not guarantees, and actual results can differ due to market dynamics, regulatory factors, and product adoption trends. Investors should consider the provided ranges and attitudes over time as part of a broader assessment rather than as a promise of performance.
Tap a question to reveal the answer.
2030: avg $116.07, min $86.69, max $167.31; ROI 61%; sentiment BULLISH.
Forecasts show a bullish sentiment from 2028 onward with rising averages (2030 avg $116.07; 2040 avg $254.48; 2050 avg $502.36) and notable ROIs (e.g., 61% in 2030 and 596.8% in 2050). These are estimates, not guarantees.
Yes. The 2035 max forecast is $260.06, and the 2040 average is $254.48, indicating potential above $200 in the mid-2020s to 2040 range.
Current price: $72.10. Market cap: $27.82B.
Near term: sentiment NEUTRAL, RSI(14) 70, SMA50 $63.46, SMA200 $67.95; support $57.56, resistance $72.10; 30-day range $60.86–$85.42.
DexCom, Inc. Community Discussion
0Share your DexCom, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.